Skip to main content
Top

10-01-2018 | Respiratory disorders | Article

Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group

Journal: Rheumatology International

Authors: D. Sánchez-Cano, N. Ortego-Centeno, J. L. Callejas, V. Fonollosa Plá, R. Ríos-Fernández, C. Tolosa-Vilella, G. Espinosa-Garriga, D. Colunga-Argüelles, M. V. Egurbide-Arberas, M. Rubio-Rivas, M. Freire, J. J. Ríos-Blanco, L. Trapiella-Martínez, M. Rodríguez-Carballeira, A. Marín-Ballvé, X. Pla-Salas, C. P. Simeón-Aznar

Publisher: Springer Berlin Heidelberg

Abstract

Objectives

To evaluate the clinical characteristics of patients with interstitial lung disease (ILD) in the setting of a large cohort of systemic sclerosis (SSc) patients, and to analyse the differences according to the SSc subtype (following the modification of classification criteria of the American College of Rheumatology for SSc proposed by LeRoy and Medsger), factors are associated with moderate-to-severe impairment of lung function, as well as mortality and causes of death.

Methods

A descriptive study was performed, using the available data from the Spanish Scleroderma Study Group.

Results

Twenty-one referral centers participated in the registry. By April 2014, 1374 patients with SSc had been enrolled, and 595 of whom (43%) had ILD: 316 (53%) with limited cutaneous SSc (lcSSc), 240 (40%) with diffuse cutaneous SSc (dcSSc), and 39 (7%) with SSc sine scleroderma (ssSSc). ILD in the lcSSc and the ssSSc subsets tended to develop later, and showed a less impaired forced vital capacity (FVC) and a ground glass pattern on high-resolution computed tomography (HRCT) less frequently, compared with the dcSSc subset. Factors related to an FVC < 70% of predicted in the multivariate analysis were: dcSSc, positivity to anti-topoisomerase I antibodies, a ground glass pattern on HCRT, an active nailfold capillaroscopy pattern, lower DLco, older age at symptoms onset, and longer time between symptoms onset and ILD diagnosis. Finally, SSc-associated mortality and ILD-related mortality were highest in dcSSc patients, whereas that related to pulmonary arterial hypertension was highest in those with lcSSc-associated ILD.

Conclusions

Our study indicates that ILD constitutes a remarkable complication of SSc with significant morbidity and mortality, which should be borne in mind in all three subgroups (lcSSc, dcSSc, and ssSSc).
Literature
1.
Tamby MC, Chanseaud Y, Guillevin L, Mouthon L (2003) New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2:152–157CrossRefPubMed
2.
Barsotti S, Bruni C, Orlandi M, Della Rossa A, Marasco E, Codullo V et al. One year in review 2017: systemic sclerosis. vol 35, clinical and experimental rheumatology. 2017. pp S3–S20
3.
Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an american college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747CrossRefPubMedPubMedCentral
4.
LeRoy EC, Medsger J (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576PubMed
5.
Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–4. https://​doi.​org/​10.​1136/​ard.​2006.​066068 CrossRefPubMedPubMedCentral
6.
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G et al (2013) Scleroderma lung disease. Eur Respir Rev 22(127):6–19. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23457159%5Cn, http://​www.​pubmedcentral.​nih.​gov/​articlerender.​fcgi?​artid=​PMC4103193
7.
McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N et al (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Care Res 57(2):318–326CrossRef
8.
Steele R, Hudson M, Lo E, Baron M (2012) Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 64(4):519–24. https://​doi.​org/​10.​1002/​acr.​21583 CrossRef
9.
Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437–2444CrossRefPubMed
10.
Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 177(11):1248–54. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18369202
11.
Al MASET (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–90. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​7378088
12.
Johnson SR (2017) Progress in the clinical classification of systemic sclerosis. Curr Opin Rheumatol. http://​insights.​ovid.​com/​crossref?​an=​00002281-900000000-99200
13.
Galiè N, Hoeper MMM, Humbert M, Torbicki a, Vachiery J-LL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34(6):1219–63. http://​raredis.​ru/​upload/​pdf_​document/​Galie-2009-Guidelines for the d.pdf%5Cnpapers3://publication/doi/10.1183/09031936.00139009%5Cn,http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19749199
14.
Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M et al (2012) Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 41(6):789–800CrossRefPubMed
15.
Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Polzleitner D, Burghuber OC et al (1990) Interstitial lung disease in progressive systemic sclerosis: High-resolution CT versus radiography. Radiology 176(3):755–9. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​2389033
16.
Steen VD, Conte C, Owens GR, Medsger TA (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289CrossRefPubMed
17.
Highland KB, Silver RM (2005) New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 17(6):737–45. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​16224252
18.
Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE (2006) Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Care Res 55(4):598–602CrossRef
19.
Steen VD. The Many Faces of Scleroderma. vol 34, Rheumatic Disease Clinics of North America. 2008. pp 1–15
20.
Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​16084222
21.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O et al (2014) Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 69(5):428–36. https://​doi.​org/​10.​1136/​thoraxjnl-2013-204202
22.
Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581–1586CrossRefPubMed
23.
Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M et al (2006) High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 33:1789–1801PubMed
24.
Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800CrossRefPubMed
25.
Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–93. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​14583573%5Cn, http://​www.​pubmedcentral.​nih.​gov/​articlerender.​fcgi?​artid=​PMC1754353
26.
Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E et al (2013) The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 15(6):R193. http://​arthritis-research.​biomedcentral.​com/​articles/​10.​1186/​ar4383
27.
Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM et al (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43(4):461–6. https://​academic.​oup.​com/​rheumatology/​article-lookup/​doi/​10.​1093/​rheumatology/​keh067
28.
Demir N, Şahin A, Küçükşahin O, Kayacan O, Dinçer İ, Sayın T et al (2014) Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience. Heart Lung Circ 23(7):667–73. http://​www.​sciencedirect.​com/​science/​article/​pii/​S144395061400070​5
29.
Steen V, Medsger TA (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48(2):516–522CrossRefPubMed
30.
Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182(2):252–260CrossRefPubMedPubMedCentral
31.
Poormoghim H, Lucas M, Fertig N, Medsger TA (2000) Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 43(2):444–451CrossRefPubMed
32.
Simeón-Aznar CP, Tolosa-Vilella C, Gabarró-Juliá L, Campillo-Grau M, Guillén Del Castillo A, Fonollosa-Plá V et al (2014) Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences. Clin Exp Rheumatol 32(6 Suppl 86):S-33–40. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24776173
33.
Christmann RB, Wells AU, Capelozzi VL, Silver RM (2010) Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. vol 40, Seminars in Arthritis and Rheumatism. pp 241–249
34.
Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA (2006) Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 36(3):173–181CrossRefPubMed
35.
Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF et al (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346–54. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11501722
36.
Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G et al (2009) Gastroesophageal reflux and pulmonary fibrosis in Scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 179(5):408–413CrossRefPubMed
37.
Cantu E, Appel JZ, Hartwig MG, Woreta H, Green C, Messier R et al (2004) J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 78(4):1142–1151. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15464462
38.
Walsh SJ, Fenster JR (1997) Geographical clustering of mortality from systemic sclerosis in the Southeastern United States, 1981–90. J Rheumatol 24(12):2348–2352PubMed
39.
Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118(1):2–10. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15639201
40.
Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44(2):208–19. http://​ac.​els-cdn.​com/​S004901721400080​8/​1-s2.​0-S004901721400080​8-main.​pdf?​_​tid=​fd33cd0a-fcf9-11e5-b222-00000aab0f27&​acdnat=​1460058813_​23657634f72f8dd6​6903c114e50239b7​
41.
Rubio-Rivas M, Simeón-Aznar CP, Velasco C, Marí-Alfonso B, Espinosa G, Corbella X et al (2017) Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin Exp Rheumatol. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28229826
42.
Rubio-Rivas M, Simeón-Aznar CP, Velasco C, Marí-Alfonso B, Espinosa G, Corbella X et al (2017) Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin Exp Rheumatol 5–12. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28229826
43.
Zuhur F, Zuhur SS, Zuhur C, Musellim B, Ongen G (2012) Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatol Int 32(6):1655–1661CrossRefPubMed
44.
Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N (2013) Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 32(10):1533–9. https://​doi.​org/​10.​1007/​s10067-013-2289-0 CrossRefPubMed
45.
Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146:422–436CrossRefPubMed
46.
Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis [Internet]. 2015;annrheumdis-2014–205897. http://​ard.​bmj.​com/​content/​early/​2015/​02/​16/​annrheumdis-2014-205897.​long
47.
Vettori S, Cuomo G, Abignano G, Iudici M, Valentini G (2011) Survival and death causes in 251 systemic sclerosis patients from a single Italian center. Reumatismo 62(3):202–9. http://​www.​reumatismo.​org/​index.​php/​reuma/​article/​view/​482
48.
Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH et al (2017) Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model. Chest. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S001236921731078​4